INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7
06 Março 2019 - 6:15PM
INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the
development, manufacture and commercialization of pharmaceutical
cannabinoids and spray technology, today announced that it will
release its fourth quarter and full year 2018 financial results on
Thursday, Mar. 7, after the U.S. financial markets close.
Following the release, Saeed Motahari, president
and chief executive officer, and Andy Long, chief financial
officer, will host a conference at 5:00 p.m. Eastern Time to
discuss the results.
Interested parties can listen to the call live
as it occurs via the company’s website, https://www.insysrx.com/,
on the Investors section’s Presentations & Events page; or by
dialing 844-263-8304 (from inside the U.S.) or 213-358-0958 (from
outside the U.S.) and using the Conference ID 9498523. A webcasted
replay of the call will be available on the site a few hours after
the event.
About INSYSINSYS Therapeutics
is a specialty pharmaceutical company that develops and
commercializes innovative drugs and novel drug delivery systems of
therapeutic molecules that improve patients’ quality of life. Using
proprietary spray technology and capabilities to develop
pharmaceutical cannabinoids, INSYS is developing a pipeline of
products intended to address unmet medical needs and the clinical
shortcomings of existing commercial products. The company is
committed to developing medications for potentially treating
anaphylaxis, epilepsy, Prader-Willi syndrome, opioid addiction and
overdose, and other disease areas with a significant unmet
need.
CONTACT:
|
Investor Relations
& Corporate Communications |
|
Jackie Marcus or Chris
Hodges |
|
Alpha IR Group |
|
312-445-2870 |
|
INSY@alpha-ir.com |
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024
Notícias em tempo-real sobre Insys Therapeutics, Inc. da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de